Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage
- PMID: 28724310
- DOI: 10.1080/03007995.2017.1358159
Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage
Abstract
Drs Godman and Fadare review the paper by Mares-Garcia and colleagues in Spain regarding the extent of non-guideline recommended prescribing (NGRP) of proton pump inhibitors (PPIs) in ambulatory care. NGRP of PPIs is an increasing public health concern given the implications of overuse of PPIs on infection rates, osteoporosis and chronic kidney disease as well as increasing polypharmacy rates. Costs are less of an issue especially where there are low prices for generic PPIs; the main focus is on improving the quality of PPI prescribing. Encouragingly, Mares-Garcia and colleagues identified key factors associated with NGRP, providing direction to others.
Keywords: Guidelines; PPIs; prescribing; public health.
Comment on
-
Non-guideline-recommended prescribing of proton pump inhibitors in the general population.Curr Med Res Opin. 2017 Oct;33(10):1725-1729. doi: 10.1080/03007995.2017.1308921. Epub 2017 Apr 19. Curr Med Res Opin. 2017. PMID: 28318318
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources